The data used for the analysis are anonymous case-based data that are included in the European Surveillance System (or TESSy) which is administrated by the European Centre for Disease Prevention and Control. Subsets of TESSy data (including the subset that was used for the current analysis) can be made available for research purposes/tasks in the public interest under certain conditions. To be granted access to the subset of TESSy data researcher should submit the Request for TESSy Data for Research form to ECDC. This form will be assessed by an internal review group and access will be granted if the request fulfils the requirements described in the Policy on data submission, access, and use of data within TESSy. Detailed information and forms can be obtained from <https://ecdc.europa.eu/en/publications-data/european-surveillance-system-tessy>.

Introduction {#sec005}
============

Tuberculosis (TB) remains a serious international public health problem today, with a disproportionate number of the 10 million new cases emerging each year being concentrated in Asia and Africa \[[@pone.0186499.ref001]\]. The countries of the European Union and European Economic Area (EU/EEA) together reported 58,008 cases in 2014 to the joint TB surveillance activities of the European Centre for Disease Prevention and Control (ECDC) and the World Health Organisation (WHO) ([Table 1](#pone.0186499.t001){ref-type="table"}), which account for about 1% of all TB cases notified globally \[[@pone.0186499.ref002]\]. Despite its relatively small and declining TB caseload, this group of 31 countries presents a very diverse TB epidemiological pattern, with low TB incidence in its western and southern regions to moderate levels moving eastwards. The large majority of TB cases in western European countries are of foreign origin or in subgroups at a higher risk of infection and disease than the general population. Overall, 75% of the TB cases show exclusive pulmonary involvement (PTB), 19% solely extrapulmonary disease (EPTB), and 6% have mixed disease \[[@pone.0186499.ref003]\]. These proportions, however, differ markedly between countries and population groups. In general, PTB patients have more severe forms of disease, as evidenced by a higher risk of dying and lower risk of completing treatment successfully when compared to the average EPTB case. Given this unfavourable prognosis, as well as the risk of direct transmissibility, PTB remains a priority for public health action in TB control. Nonetheless, EPTB also presents public health concerns given that it often challenges diagnosis (particularly in children), and it could have clinically significant sequelae \[[@pone.0186499.ref004]\]. A number of high-income countries have reported an increased frequency of EPTB over time \[[@pone.0186499.ref003],[@pone.0186499.ref005],[@pone.0186499.ref006]\]. Site of disease has been reported to differ substantially by geography and by other risk factors \[[@pone.0186499.ref003], [@pone.0186499.ref007]--[@pone.0186499.ref010]\].

10.1371/journal.pone.0186499.t001

###### Demographic and clinical characteristics of tuberculosis cases notified in 31 European Union and European Economic Area countries, by site of disease, 2003--2014.

![](pone.0186499.t001){#pone.0186499.t001g}

  Characteristics                                                     Sites    Total                                                        
  ------------------------------------------------------------------- -------- ------- -------- ----- ------- ----- ------- ------ -------- -----
  **Year of report**                                                                                                                        
  2003                                                                51937    8%      14184    8%    5593    10%   14882   31%    86596    9%
  2004                                                                60368    10%     14914    8%    5206    9%    3287    7%     83775    9%
  2005                                                                58903    9%      14428    8%    4965    9%    2419    5%     80715    9%
  2006                                                                55314    9%      14724    8%    4554    8%    1447    3%     76039    8%
  2007                                                                56520    9%      14566    8%    4900    9%    8033    17%    84019    9%
  2008                                                                54502    9%      15317    9%    4836    9%    8429    18%    83084    9%
  2009                                                                52089    8%      15353    9%    4440    8%    7770    16%    79652    9%
  2010                                                                53894    9%      16863    9%    4628    8%    190     0%     75575    8%
  2011                                                                51290    8%      16056    9%    4784    8%    233     0%     72363    8%
  2012                                                                48720    8%      15806    9%    4350    8%    114     0%     68990    8%
  2013                                                                45743    7%      14468    8%    4438    8%    172     0%     64821    7%
  2014                                                                41076    7%      12678    7%    3982    7%    272     1%     58008    6%
  **Age group** (years)                                                                                                                     
  \< 15                                                               13946    2%      14075    8%    6208    11%   2880    6%     37109    4%
  15--44                                                              289339   46%     89865    50%   27943   49%   22687   48%    429834   47%
  45--64                                                              211789   34%     40790    23%   12731   22%   11834   25%    277144   30%
  ≥ 65                                                                113985   18%     34304    19%   9726    17%   9544    20%    167559   18%
  Unknown                                                             1297     0%      323      0%    68      0%    303     1%     1991     0%
  **Sex**                                                                                                                                   
  Female                                                              203080   32%     82761    46%   20628   36%   17455   37%    323924   35%
  Male                                                                426530   68%     96309    54%   35939   63%   29414   62%    588192   64%
  Unknown                                                             746      0%      287      0%    109     0%    379     1%     1521     0%
  **Previous TB treatment**[\*](#t001fn001){ref-type="table-fn"}                                                                            
  No                                                                  489667   78%     152501   85%   47109   83%   39356   83%    728633   80%
  Yes                                                                 99982    16%     7478     4%    3630    6%    3308    7%     114398   13%
  Unknown                                                             40707    6%      19378    11%   5937    10%   4584    10%    70606    8%
  **Region of origin**[\*\*](#t001fn002){ref-type="table-fn"}                                                                               
  Western Europe                                                      114653   18%     39764    22%   10876   19%   3799    8%     169092   19%
  Central Europe, EU since 2004                                       400434   64%     60371    34%   22663   40%   1987    4%     485455   53%
  Other Central / Eastern Europe                                      10787    2%      1730     1%    861     2%    576     1%     13954    2%
  Africa                                                              25133    4%      21641    12%   6185    11%   2219    5%     55178    6%
  Indian subcontinent                                                 14300    2%      24573    14%   5052    9%    647     1%     44572    5%
  Rest of Asia                                                        15835    3%      8914     5%    2642    5%    1137    2%     28528    3%
  Americas & Oceania                                                  4911     1%      2163     1%    570     1%    377     1%     8021     1%
  Unknown                                                             44303    7%      20201    11%   7827    14%   36506   77%    108837   12%
  **Country of report**                                                                                                                     
  Austria                                                             7074     1%      1732     1%    798     1%    4       0%     9608     1%
  Belgium                                                             7822     1%      3529     2%    1193    2%    2       0%     12546    1%
  Bulgaria                                                            14453    2%      4980     3%    803     1%    1       0%     20237    2%
  Croatia                                                             1318     0%      140      0%    58      0%    73      0%     1589     0%
  Cyprus                                                              406      0%      121      0%    23      0%    2       0%     552      0%
  Czech Republic                                                      7428     1%      1561     1%    445     1%    0       0%     9434     1%
  Denmark                                                             2557     0%      824      0%    166     0%    963     2%     4510     0%
  Estonia                                                             4211     1%      401      0%    423     1%    0       0%     5035     1%
  Finland                                                             2742     0%      1171     1%    0       0%    0       0%     3913     0%
  France                                                              37482    6%      16630    9%    8817    16%   915     2%     63844    7%
  Germany                                                             41348    7%      13186    7%    5629    10%   623     1%     60786    7%
  Greece                                                              3447     1%      601      0%    399     1%    2882    6%     7329     1%
  Hungary                                                             18479    3%      1036     1%    246     0%    0       0%     19761    2%
  Iceland                                                             59       0%      54       0%    18      0%    0       0%     131      0%
  Ireland                                                             3124     0%      1520     1%    397     1%    21      0%     5062     1%
  Italy                                                               31387    5%      11898    7%    1862    3%    1       0%     45148    5%
  Latvia                                                              10270    2%      1260     1%    631     1%    1726    4%     13887    2%
  Liechtenstein                                                       4        0%      1        0%    0       0%    0       0%     5        0%
  Lithuania                                                           23017    4%      3118     2%    7       0%    0       0%     26142    3%
  Luxembourg                                                          334      0%      45       0%    3       0%    29      0%     411      0%
  Malta                                                               250      0%      122      0%    46      0%    1       0%     419      0%
  Netherlands                                                         4505     1%      4347     2%    1166    2%    2672    6%     12690    1%
  Norway                                                              2083     0%      1431     1%    360     1%    106     0%     3980     0%
  Poland                                                              82639    13%     6579     4%    530     1%    10124   21%    99872    11%
  Portugal                                                            24503    4%      8624     5%    2285    4%    1175    2%     36587    4%
  Romania                                                             224583   36%     38813    22%   18278   32%   17      0%     281691   31%
  Slovakia                                                            5282     1%      1255     1%    382     1%    0       0%     6919     1%
  Slovenia                                                            1680     0%      408      0%    364     1%    2       0%     2454     0%
  Spain                                                               22399    4%      8344     5%    0       0%    23576   50%    54319    6%
  Sweden                                                              2332     0%      1965     1%    527     1%    1925    4%     6749     1%
  United Kingdom                                                      43138    7%      43661    24%   10820   19%   408     1%     98027    11%
  **HIV infection**                                                                                                                         
  Positive                                                            3866     1%      1511     1%    816     1%    7       0%     6200     1%
  Negative                                                            84890    13%     18082    10%   5148    9%    125     0%     108245   12%
  Unknown                                                             541600   86%     159764   89%   50712   89%   47116   100%   799192   87%
  **Culture result**                                                                                                                        
  Positive                                                            434638   69%     59974    33%   35075   62%   24633   52%    554320   61%
  Negative                                                            118063   19%     31452    18%   11391   20%   8863    19%    169769   19%
  Unknown                                                             77655    12%     87931    49%   10210   18%   13752   29%    189548   21%
  **Multidrug resistance**[\*\*\*](#t001fn007){ref-type="table-fn"}                                                                         
  Yes                                                                 14609    4%      563      1%    558     2%    213     2%     15943    4%
  No                                                                  205256   57%     40821    77%   20033   72%   4742    51%    270852   60%
  Unknown                                                             139845   39%     11651    22%   7167    26%   4345    47%    163008   36%

\* Cases without a previous TB diagnosis but with no information on treatment history were considered new cases;

\*\* Western Europe includes European countries not included in Central or Eastern Europe;

Central Europe, EU since 2004 is composed of Bulgaria, Croatia, Czech Rep, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovenia and Slovakia;

Other Central / Eastern Europe includes all other Central European countries in the Balkans as well as Belarus, Moldova Rep., the Russian Federation and Ukraine;

The Indian subcontinent is composed of Bangladesh, Bhutan, British Indian Ocean Territory, Comoros Islands, India, Maldives, Nepal, Pakistan and Sri Lanka;

Rest of Asia includes the former Soviet Central Asian republics, and other Asian countries not in the Indian subcontinent or Oceania.

\*\*\* Resistance to isoniazid and rifampicin in cases with a strain reported as M.tuberculosis complex, M.tuberculosis, M.bovis, or M.africanum

In the EU/EEA, the reporting of case-based data for the European-level surveillance of TB dates back to the mid-1990s. These data allow an in-depth study of epidemiological patterns and determinants of outcomes (e.g. drug resistance, death). In this paper, we analyse data reported by various EU/EEA countries in the 12 most recent years to identify demographic and clinical host-related factors associated with the site of disease among TB cases.

Materials & methods {#sec006}
===================

Data sources and collection {#sec007}
---------------------------

Surveillance data described in this article were reported within the framework of collaborative surveillance of TB in Europe through a network of national TB surveillance authorities \[[@pone.0186499.ref011],[@pone.0186499.ref012]\]. Reporting has followed a standardised methodology allowing comparison between countries and over time \[[@pone.0186499.ref013]--[@pone.0186499.ref016]\]. Anonymous case-based data are now consolidated as part of the European Surveillance System (or TESSy) by the European Centre for Disease Prevention and Control (ECDC; [www.ecdc.europa.eu](http://www.ecdc.europa.eu)), based in Sweden. Until 2007, the European TB data collection was coordinated by a dedicated network (EuroTB) coordinated by the French Institut de Veille Sanitaire, a WHO Collaborating Centre.

Inclusion criteria and definitions {#sec008}
----------------------------------

For this analysis, PTB is defined as TB of the lung parenchyma, tracheo-bronchial tree, or larynx, while EPTB refers to TB affecting any other anatomical site. The preferred method of reporting site of disease requires information on both the major and minor localisation, as well as details of the specific site of EPTB disease. This method allows reporting of up to two sites; if more than two sites are present in an individual patient, only the two main sites are included. The following groupings of EPTB cases were used: pleural, lymphatic (both intra-thoracic and extra-thoracic), osteo-articular (spine, bone, and joint), central nervous system (CNS; including meningeal site), genito-urinary (kidney, ureter, bladder, genital tract), peritoneal/digestive tract and disseminated (including TB of \>two organ systems, miliary TB or the isolation of *Mycobacterium tuberculosis* from the blood). In order to explore determinants of specific disease localisation, only patients with either exclusive PTB or exclusive EPTB were retained in the analysis (45,636 exclusions made for patients with both PTB and EPTB involvement or with two EPTB sites; [Fig 1](#pone.0186499.g001){ref-type="fig"}).

![Selection of records for the analysis of determinants of site of TB, EU/EEA countries, 2003--2014.](pone.0186499.g001){#pone.0186499.g001}

Country of origin was defined by birth in all included countries except for Austria and Belgium where it was defined by citizenship. Countries were classified in seven geographical groups, namely Africa, Americas & Oceania, Europe (three subgroupings), the Indian subcontinent, and the Rest of Asia ([Fig 2](#pone.0186499.g002){ref-type="fig"}; [Table 1](#pone.0186499.t001){ref-type="table"} footnote). The three European subgroupings were: Central European countries which joined the EU since 2004 (Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, and Slovenia); other Central and Eastern Europe (Belarus, Republic of Moldova, the Russian Federation and Ukraine as well as all other Central European countries in the Balkans); and Western Europe (the remaining countries). The Indian subcontinent grouped the following Asian countries: Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka. Rest of Asia consisted of other countries in the region not in the Indian subcontinent or Oceania, and includes Central Asia ([Fig 2](#pone.0186499.g002){ref-type="fig"}).

![Regional grouping of countries of origin used in the analysis of determinants of site of TB, EU/EEA countries, 2003--2014.\
The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.](pone.0186499.g002){#pone.0186499.g002}

Children were defined as individuals who were under 15 years of age at the time of the report; elderly were those over 64 years. Previous TB treatment referred to chemotherapy given for active TB disease for more than four weeks and started in a calendar year before the year of report. Cases without a previous TB diagnosis and with no information on treatment history were considered new cases. Culture confirmation referred to the isolation of *M*. *tuberculosis* complex. Multidrug resistance (MDR-TB) was defined as *in vitro* resistance to at least isoniazid and rifampicin in a strain reported as *M*. *tuberculosis* complex, *M*. *tuberculosis*, *M*. *bovis*, or *M*. *africanum* on tissue samples taken at the start of treatment.

The study period consisted of the 12 consecutive years from 2003 to 2014 inclusive. Countries eligible for inclusion in this analysis were the 28 belonging to the EU as in 2014, as well as Iceland, Liechtenstein and Norway ([Table 1](#pone.0186499.t001){ref-type="table"}). Countries which did not report complete details of EPTB localisation were not included in the analysis (Finland, Lithuania, Spain and the United Kingdom); records from other countries were excluded for earlier years when no data were reported for site of disease (Denmark, Latvia, Poland and Sweden) or patient geographic origin (France, Norway and Poland) ([Fig 1](#pone.0186499.g001){ref-type="fig"}).

Statistical analysis {#sec009}
--------------------

The 'null hypothesis' of no association between site and putative explanatory variables was tested using data from all countries pooled for all available years. Bivariate and multivariable analyses were restricted to cases with full data on site, sex, age, TB treatment history, and geographic origin. Owing to the large proportion of cases without information on (i) susceptibility to isoniazid and rifampicin and (ii) HIV status ([Table 1](#pone.0186499.t001){ref-type="table"}), the analysis did not consider these variables.

Crude odds ratios (OR) with 95% confidence intervals (95% CI) were used to express magnitude of association between categorical variables in bivariate analysis ([Table 2](#pone.0186499.t002){ref-type="table"}). Pearson's χ2 was used to test relationships and a p-value\<0.05 was considered statistically significant and was also used as the threshold to include variables in the logistic regression (see below).

10.1371/journal.pone.0186499.t002

###### Bivariate and multivariable (logistic regression) analysis for risk factors associated with exclusive extrapulmonary tuberculosis in 27 European Union and European Economic Area countries[^1^](#t002fn002){ref-type="table-fn"}, 2003--2014 (N = 564,916 cases with full data).

![](pone.0186499.t002){#pone.0186499.t002g}

  Risk factors                                                      Sites    Bivariate   Multivariable                                                   
  ----------------------------------------------------------------- -------- ----------- --------------- ----- -------- ----- ------ ------------ ------ ------------
  **Age group** (years)                                                                                                                                  
  \< 15                                                             7966     2%          9417            10%   17383    3%    5.84   5.64--6.03   5.50   5.32--5.68
  15--44                                                            213019   45%         43112           45%   256131   45%   1      reference    1.00   reference
  45--64                                                            168373   36%         23042           24%   191415   34%   0.68   0.66--0.69   0.88   0.86--0.89
  ≥ 65                                                              80555    17%         19432           20%   99987    18%   1.19   1.17--1.21   1.26   1.24--1.29
  **Sex**                                                                                                                                                
  Female                                                            146301   31%         43296           46%   189597   34%   1.85   1.82--1.88   1.60   1.58--1.63
  Male                                                              323612   69%         51707           54%   375319   66%   1      reference    1      reference
  **Previous TB treatment**[^2^](#t002fn003){ref-type="table-fn"}                                                                                        
  No                                                                381915   81%         90155           95%   472070   84%   1      reference    1      reference
  Yes                                                               87998    19%         4848            5%    92846    16%   0.23   0.23--0.24   0.32   0.31--0.33
  **Region of origin**                                                                                                                                   
  Western Europe                                                    68131    14%         21447           23%   89578    16%   1      reference    1      reference
  Central Europe, EU since 2004                                     364087   77%         55116           58%   419203   74%   0.48   0.47--0.49   0.57   0.56--0.58
  Other Central / Eastern Europe                                    8541     2%          1339            1%    9880     2%    0.50   0.47--0.53   0.52   0.49--0.56
  Africa                                                            12607    3%          8291            9%    20898    4%    2.09   2.02--2.16   2.29   2.22--2.38
  Indian subcontinent                                               3300     1%          3377            4%    6677     1%    3.25   3.09--3.42   3.74   3.56--3.94
  Rest of Asia                                                      10611    2%          4547            5%    15158    3%    1.36   1.31--1.41   1.47   1.42--1.53
  Americas & Oceania                                                2636     1%          886             1%    3522     1%    1.07   0.99--1.15   1.08   0.99--1.16

EU, European Union; OR, Odds ratio; aOR, adjusted OR; 95%CI, 95% confidence limits

^1^ Including countries listed in [Table 1](#pone.0186499.t001){ref-type="table"} with the exception of Finland, Lithuania, Spain, and the United Kingdom (see [Fig 2](#pone.0186499.g002){ref-type="fig"} and [Materials and methods](#sec006){ref-type="sec"} for more detail on exclusion of data)

^2^ Cases without a previous TB diagnosis and with no information on treatment history were considered new cases

Two multivariable regression analyses were performed. Binary logistic regression was first used to identify variables independently associated with exclusive EPTB disease ([Table 2](#pone.0186499.t002){ref-type="table"}). Multinomial logistic regression was used to compare the risk factors for different forms of EPTB, using PTB as a reference ([Table 3](#pone.0186499.t003){ref-type="table"}). To simplify the presentation, the results of multinomial regression are shown without adjustment for interaction. Adjusted ORs (aORs) were used to quantify the magnitude of associations.

10.1371/journal.pone.0186499.t003

###### Risk factors associated with different forms of extrapulmonary tuberculosis (N = 95,003) compared to pulmonary tuberculosis (N = 469,913) in 27 countries of the European Union and European Economic Area, 2003--2014.

![](pone.0186499.t003){#pone.0186499.t003g}

  Risk factors                      Pleural   Lymphatic    Osteo-articular   Genito-urinary   Central nervous system   Peritoneal & Digestive   Disseminated   Other                                                                              
  --------------------------------- --------- ------------ ----------------- ---------------- ------------------------ ------------------------ -------------- ------------ ------- -------------- ------ ------------ ------ ------------ ------ ------------
  **Age group** (years)                                                                                                                                                                                                                           
  \< 15                             1.93      1.83--2.04   17.96             17.21--18.74     4.48                     4--5.02                  0.53           0.37--0.75   11.41   10.29--12.65   2.21   1.8--2.73    2.58   1.93--3.43   3.73   3.32--4.18
  15--44                            1         reference    1                 reference        1                        reference                1              reference    1       reference      1      reference    1      reference    1      reference
  45--64                            0.57      0.55--0.58   0.93              0.9--0.97        1.95                     1.85--2.07               2.43           2.28--2.6    0.96    0.87--1.05     1.03   0.94--1.13   0.88   0.75--1.02   1.62   1.53--1.72
  ≥ 65                              0.75      0.72--0.77   1.52              1.46--1.57       3.33                     3.14--3.53               3.35           3.12--3.59   1.07    0.96--1.19     1.25   1.12--1.39   1.24   1.06--1.45   2.39   2.25--2.54
  Female sex                        1.08      1.06--1.11   2.55              2.49--2.62       1.63                     1.56--1.7                1.78           1.69--1.87   1.58    1.47--1.7      2.02   1.87--2.18   1.23   1.09--1.39   2.31   2.2--2.42
  Previous TB treatment             0.15      0.14--0.15   0.48              0.45--0.5        0.59                     0.55--0.63               0.45           0.41--0.5    0.42    0.37--0.49     0.45   0.38--0.52   0.54   0.43--0.69   0.52   0.48--0.57
  **Region of origin**                                                                                                                                                                                                                            
   Western Europe                   1         reference    1                 reference        1                        reference                1              reference    1       reference      1      reference    1      reference    1      reference
   Central Europe, EU since 2004    1.08      1.05--1.11   0.37              0.36--0.38       0.53                     0.5--0.56                0.3            0.28--0.32   0.55    0.51--0.6      0.36   0.33--0.4    0.09   0.08--0.1    0.31   0.3--0.33
   Other Central / Eastern Europe   0.49      0.44--0.54   0.65              0.59--0.72       0.59                     0.49--0.71               0.59           0.5--0.7     0.59    0.45--0.78     0.41   0.29--0.59   0.29   0.19--0.46   0.29   0.23--0.36
   Africa                           0.86      0.8--0.92    4.65              4.43--4.88       3.83                     3.51--4.17               1.06           0.93--1.21   1.88    1.61--2.19     4.64   4.1--5.25    2.21   1.86--2.61   2.57   2.36--2.8
   Indian subcontinent              1.23      1.1--1.37    8.84              8.27--9.45       6.83                     6.06--7.7                1.23           0.97--1.55   2.46    1.93--3.15     6.36   5.33--7.58   2.97   2.31--3.81   3.72   3.27--4.24
   Rest of Asia                     0.59      0.54--0.65   3.22              3.06--3.4        1.48                     1.31--1.66               0.9            0.79--1.03   0.96    0.77--1.18     2.07   1.77--2.43   0.5    0.36--0.68   1.09   0.97--1.23
   Americas & Oceania               0.72      0.62--0.84   1.69              1.51--1.9        1.12                     0.86--1.46               0.57           0.41--0.81   1       0.68--1.46     2.22   1.69--2.91   0.78   0.48--1.27   1.26   1.03--1.55

aOR, Adjusted Odds Ratios from multinomial regression analysis; EU, European Union; 95% CI, 95% confidence limits

Values not adjusted for clustering by country of report or for year of report

Maps were created with R (using *ggplot2* package) working within R Studio \[[@pone.0186499.ref017]\]. Logistic regression was done with R (*glm* function) and multinomial regression with STATA version 12.1 (StataCorp, College Station, Texas).

Results {#sec010}
=======

Description {#sec011}
-----------

The thirty-one EU/EEA countries reported a total of 913,637 TB cases, fairly evenly spread over the 12-year period ([Table 1](#pone.0186499.t001){ref-type="table"}). Half the included cases were from Romania (31%), Poland (11%) and the United Kingdom (11%). Out of all cases reported, 69% were exclusively PTB, 20% were exclusively EPTB, 6% had both PTB and EPTB, and 5% had an unknown site. Culture confirmation was more frequent in PTB (69%) than in exclusive EPTB cases (33%), half of whom had no culture result. Multidrug resistance was confirmed in 4% of PTB cases and 1% of EPTB, with 36% overall having no result. HIV infection was recorded in 1% overall but 87% of cases had no information.

After exclusion of cases without key data, 564,916 records (62%; [Table 2](#pone.0186499.t002){ref-type="table"}; Figs [1](#pone.0186499.g001){ref-type="fig"} and [3](#pone.0186499.g003){ref-type="fig"}) from twenty-seven countries were retained. The characteristics of the cases for the variables of interest had a similar distribution to the one of the whole population before restriction; the only exception is in the proportion of cases from the Central European EU countries (53% in complete dataset and 74% after exclusions; Tables [1](#pone.0186499.t001){ref-type="table"} and [2](#pone.0186499.t002){ref-type="table"}). Seventeen percent of cases had exclusively EPTB. Children and the elderly accounted for smaller proportions of the PTB (2% and 17% respectively) when compared with EPTB cases (10% and 20%). The ratio of males to females was 1.2 among the EPTB cases, but was 2.2 among the PTB cases. More of the EPTB cases were previously untreated for TB (95%) than PTB cases (81%). Only 6% of PTB cases originated from outside Europe, with most reported from Romania and other Central European EU countries. In contrast, a larger proportion of EPTB cases originated from Western Europe (23%), Africa (9%) and Asia (8%). Among the 95,003 exclusively EPTB cases, the most frequent localizations reported were pleural (40%), lymphatic (29%), osteoarticular (9%), and genito-urinary (6%) ([Table 3](#pone.0186499.t003){ref-type="table"}). The more severe forms of EPTB---CNS (3%) and disseminated (1%)---were relatively uncommon.

![Distribution of TB cases in the 27 countries included in the multivariable analysis of determinants of site of TB, EU/EEA countries, 2003--2014.\
SOURCE OF GRAPHIC: ECDC Map Maker (EMMa), available at <https://emma.ecdc.europa.eu>\
The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.](pone.0186499.g003){#pone.0186499.g003}

Analysis {#sec012}
--------

At bivariate analysis, the strongest, statistically significant positive associations with EPTB were observed with being a child (OR = 5.84), not previously treated for TB (4.28; 0.23 if previously treated), being from Africa (2.09 compared with Western Europe) or the Indian subcontinent (3.25), or female (1.85) ([Table 2](#pone.0186499.t002){ref-type="table"}). The adjusted ORs from logistic regression reproduced the magnitude and direction of associations observed at bivariate analysis. Year of report bore no relationship to the site of disease.

At multinomial regression ([Table 3](#pone.0186499.t003){ref-type="table"}), an origin from the Indian subcontinent or Africa was most strongly associated with lymphatic, osteoarticular and peritoneal/digestive localization (aOR at least 3.83). Age \<15 years was most strongly associated with lymphatic and central nervous system disease (aOR at least 11.41), but all types of EPTB were more likely in childhood, with the exception of genito-urinary TB which was associated with age 45--64 years and \>64 years (aORs 2.43 and 3.35 respectively). Female sex was significantly associated with all forms of EPTB, especially lymphatic forms (2.55). Patients with a previous history of TB treatment were less likely to have EPTB, regardless of form (aORs ranging from 0.15 in pleural to 0.59 in osteoarticular).

Discussion {#sec013}
==========

We explored pooled, case-based surveillance data reported by EU/EEA countries for twelve recent years to identify factors associated with the site of disease in notified TB patients. We observed that EPTB was more likely at the extremes of age, in females, in individuals not previously treated for TB, and in patients who were of African or Asian ethnicity. These findings are important for the post-2015 End TB Strategy with its stress on treating all forms of TB \[[@pone.0186499.ref018]\].

Our analysis quantifies the differential effects of demographic and clinical factors on the disease manifestation using a multinational routine surveillance database which has been consolidated over several years through the long-standing commitment of a vigorous network of public health workers \[[@pone.0186499.ref011]\]. Two important strengths of the dataset we used were its diversity in terms of patient mix in the countries of the EU/EEA and its size---more than half a million cases from 27 countries could be included in the main analysis. This allowed, for instance, a grouping of patients into geographical subsets in which meaningful patterns of TB localization could be discerned. These included regions of the world from where such information is otherwise sparse.

The effect of age and sex on site of TB disease that we report concurs with what has been described from various settings, albeit with a much larger geographic span and number of observations \[[@pone.0186499.ref019]--[@pone.0186499.ref026]\]. In our study, the risk for most types of EPTB was associated with the extremes of age (\<15 and \>64 years), possibly reflecting the performance of an immune system which is still maturing in infancy and childhood or declining with advancing age. The associations we have described between EPTB and female sex have been reported in different parts of the world \[[@pone.0186499.ref009],[@pone.0186499.ref027],[@pone.0186499.ref028]\]. They may be influenced in part by a higher frequency of smoking in males, which is known to predispose to PTB \[[@pone.0186499.ref027]\].

Our analysis has shown a clear association between certain forms of EPTB and the geographic origin of patients. After adjustment for age, sex, and TB treatment history, cases originating from India, Africa, and Asia were more likely to develop EPTB than cases originating from Europe and Americas, with aORs ranging between 1.5 and 3.7. For lymphatic, osteoarticular and peritoneal/digestive EPTB, the association with an origin from the Indian subcontinent was the highest of all regional variations observed, ranging from 6.4 to 8.8. The association between EPTB and ethnicity was demonstrated in other studies, suggesting a relationship between the genetic background of the host and some *M*. *tuberculosis* genotypes which are more prevalent in some geographical areas \[[@pone.0186499.ref029],[@pone.0186499.ref030]\]. Host predisposition for TB and for certain forms of disease based on human genetic characteristics have been described, although the relationship with any particular site was not strong \[[@pone.0186499.ref031],[@pone.0186499.ref032]\].

In the dataset we analysed, severe forms of EPTB (CNS and disseminated) were relatively uncommon. Challenges remain to diagnose EPTB, including in well-resourced, high-income settings where TB is becoming increasingly rare \[[@pone.0186499.ref033]\]. Delays in diagnosis and treatment of EPTB predispose to progression of disease. Maintaining a higher index of suspicion thus remains important, bearing in mind the protean manifestations of TB. The use of appropriate diagnostics is key, particularly molecular techniques which are now validated for the diagnosis of several forms of EPTB and for use in children \[[@pone.0186499.ref034],[@pone.0186499.ref035]\].

Some limitations in our analysis should be highlighted. The authors had no means of independently verifying the quality of reporting and any differences in the validity of report between countries and over time. However, most institutions belonging to this European network have been using a fairly standardised reporting methodology for many years. The variables in the ECDC TESSy database do not include those for certain risk factors that are known to influence progression and form of TB disease, such as the delay to start of treatment, adequacy of treatment administered, diabetes, cancer, and other comorbidities, immunosuppressive therapy tobacco smoking, and alcohol consumption \[[@pone.0186499.ref020],[@pone.0186499.ref021],[@pone.0186499.ref036]--[@pone.0186499.ref039]\]. Moreover, incomplete information on susceptibility to isoniazid and rifampicin and on HIV status precluded the investigation of their potential associations with TB localisation within the scope of our analysis. While it may be difficult to harmonise variables about modifiable risk factors like alcohol use and smoking within multinational databases such as TESSy, it may be feasible to do so at national level and explore associations which could guide frontline staff in their work. Finally, it may be useful in the future to use TB strain genotype data being collated within TESSy to explore transmission at the molecular level.

In conclusion, it is likely that the predilection for TB site of disease is determined by a complex interplay between the microbiology and host genetic, behavioural, clinical and demographic features \[[@pone.0186499.ref040],[@pone.0186499.ref041]\]. Our analysis sheds light on the determinants of TB localisation from a surveillance dataset spanning a broad swathe of the global population, extending well beyond the high- and middle-income settings of the western and central European countries reporting the data. The fact that our findings correspond to those described elsewhere attests to the utility of routinely collected data for planning and decision-making. It is likely that EPTB will remain a topic of discussion in TB care and prevention, especially given that issues such as early case finding, childhood TB, improved diagnostics, and more effective treatment for all forms of TB remain integral to the implementation of the post-2015 End TB Strategy and to TB elimination in low-incidence settings \[[@pone.0186499.ref018],[@pone.0186499.ref042]\].
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